

Purification of cellular membranes enriched in CCR5 or CD4 and preparation of the corresponding proteoliposomes

Thus, it is possible to reconstitute receptors in
5 liposomes containing the following, starting from Sf9 cellular membranes:

1. CCR5 only,
2. CD4 only,
3. CCR5 and CD4 in proportions chosen from cells
10 expressing CCR5 and CD4 separately,
4. CCR5 and CD4 in chosen proportions starting from cells expressing CCR5 and CD4 at the same time, and in identical quantities.

The objective is to obtain HIV envelopes fusion
15 with the HIV co-receptor and then to stop this fusion using a binding agent such as paraformaldehyde or glutaraldehyde and to inject this immunizing pair into huCD4/huCCR5 transgenic mice or into macaques or other monkeys. It may then be possible to inject the
20 preparations into man, depending on the results.

The same system is set up for CXCR4.

Strategies for the reconstitution of transmembrane proteins in proteoliposomes

25 SF9 cells of *Autographa californica*, that overexpress CCR5 (or CXCR4) and/or CD4 receptors, will be digested by appropriate detergents in order to obtain proteoliposomes using a method derived from Rigaud et al., 1988, *Biochemistry*, 27, 2677-2688,
30 Paternostre et al., *Biochemistry* 1988, 27, 2668-2677; Gaymard et al., *J. Biol. Chem.* 1996, 271, 22863-22870.

Evaluation of the functional capacities of CCR5 and/or CD4

1 - expressed at the surface of Sf9 cells

5 a) Presence of receptors at the cellular surface analysed by FACS and confocal microscopy:

I. With specific anti-CD4 or anti-CCR5 antibodies,

II. With gp120 marked by specific antibodies,

10 III. With HIV-1 carrying muted or unmuted envelopes,

IV. Initially, the function of receptors on the surface of Sf9 cells is characterized and the number of molecules per cell for which we know the lipidic environment of cellular cells, is quantified by scatchard (Cahoreau et al above).

20 b) Specific confocal fluorescence analysis of fusion by methods derived from Robert Blumenthal (NIH, personal communication, 2000) and by Vidal et al.'s methods, 1996, J. Biol. Chem. 270, 17823-17829.

I. After contact with cells expressing the HIV-1 envelope (muted or not muted),

II. After contact with HIV-1 (or viral pseudotypes carrying muted or unmuted envelopes),

25 III. With viral pseudo-particles.

2-in the corresponding proteoliposomes

a) Specific confocal fluorescence analysis using the above methods

30 b) Other energy transfer methods (FRET: Fluorescence resonance energy transfer, Mattjus et al., 1999, Anal. Biochem. 268, 297-304).

CCR-5, Introduction of 6 Histidine residues in C-terminal

- 1 - Amplification by PCR of the C-terminal region
 5 between the EcoRI site and the TGA for CCR5:

5' 3'
 CCT TCC AGG AAT TCT TTG GCC

Bac-CCR5: add a StuI site (created by
 degeneration of the genetic code) and an XbaI site into
 10 this oligonucleotide, for reintegration of the muted
 fragment into the original plasmide.

| | | | | |
|----|-----|---------|-----|-------------|
| | Val | gly | leu | opa |
| | GTG | GGC | TTG | TGA- |
| 15 | CTC | GGA | TTA | |
| | GTA | GGT | CTA | |
| | GTT | GGG | CTG | |
| | | | CTC | |
| | | | CTT | |
| 20 | | StuI | | XbaI |
| | 5' | | | 3' |
| | G | CAA | ATA | TCT |
| | C | CTT | TAT | ACA |
| | 3' | C | AT | CCG |
| | | GAC | ACT | GTA |
| | | GAT | CTC | CAC |
| | | | 5' | |
| 25 | | matched | | not matched |

The amplified EcoRI-XbaI fragment is cloned in a
 pUC vector in EcoRI-XbaI and is then sequenced. The
 30 muted fragment is then reinserted in the original
 EcoRI-XbaI plasmide.

2 - Introduction of the 6 histidine codons on the
output side of the CCR5 C-terminal

- 35 The plasmide thus modified is cut by StuI and Xba
 and is then bonded with the StuI-XbaI DNA fragment
 described below. This fragment carries 6 Histidine
 codons and a Stop TAA codon.

1/2 EcoRI StuI BamHI 1/2XbaI

AA TTC-A GGC CTG CAC-CAT-CAC-CAT-CAT-CAC TAA GGATCC T
G T CCG GAC GTG-GTA-GTG-GTA-GTA-GTG ATT CCTAGG AGATC

- An Eco-RI site is added on the input side to clone
5 oligonucleotides matched in an intermediate pUC vector,
and thus to verify the sequence.

Modification and cloning of CD4

- 10 1 - Sequencing of the C-terminal region of the pGEM-T
plasmide containing the CD4 gene:

The C-terminal region of the plasmide is verified by
sequencing after a PCR* step.

- 15 2 - Addition of 6 histidine residues in the CD4 C-
terminal:

1-Amplification of the Bsu361-BamHI region by PCR (in the polylinker)

- 20 PCR oligonucleotide:

FOR-CD4:

5'

3'

CCT AAGCTG ATG CTG AGC TTG

BAC-CD4:

- 25 BamHI PstI

5'

3'

CAGT GGATCC AAT GCG GCT GCA GGT CTT CTC

2-Addition of 6 His codons

- 30 1/2 PstI 1/2 BamHI

GC CCC ATT CAC CAT CAT CAC CAC CAT TTA G

ACCTCG GCG TAA GTG GTA GTA GTG GTG GTA ATT CCTAG